SCHEMBL11028680

SCHEMBL11028680

CCN1Cc2c(Oc3ccc(NS(=O)(=O)c4cc(Cl)ccc4OC)cc3F)ccnc2NC1=O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AXL P30530 11/20 0.49
ALPL P05186 3/20 0.46
LMNA P02545 1/20 0.46
HTT P42858 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
TP53 P04637 2/20 0.45
BRAF P15056 1/20 0.43
PLK4 O00444 1/20 0.43
AURKA O14965 1/20 0.43
GAK O14976 1/20 0.43
RIPK2 O43353 1/20 0.43
PRKAB2 O43741 1/20 0.43
ERN1 O75460 1/20 0.43
STK10 O94804 1/20 0.43
MAP4K4 O95819 1/20 0.43
EGFR P00533 1/20 0.43
FYN P06241 1/20 0.43
YES1 P07947 1/20 0.43
LYN P07948 1/20 0.43
MET P08581 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11032445 0.91 AXL (0.43) AXLALPLBRAFPLK4AURKA
SCHEMBL11030763 0.89 AXL (0.43) AXLLMNAHTTMETTHRB
SCHEMBL1160873 0.87 AXL (0.43) AXLEGFRMET
SCHEMBL11028053 0.85 AXL (0.43) AXLLMNAHTTEGFRMET
SCHEMBL11030275 0.85 AXL (0.42) AXLLMNAHTTEGFRMET
SCHEMBL11033694 0.85 AXL (0.48) AXLALPLLMNAHTTNPSR1
SCHEMBL11031202 0.84 AXL (0.40) AXLBRAFPLK4AURKAGAK
SCHEMBL11031935 0.84 AXL (0.48) AXLBRAFPLK4AURKAGAK
SCHEMBL11032009 0.84 AXL (0.46) AXLBRAFPLK4AURKAGAK
SCHEMBL1161227 0.83 BRD4 (0.42) AXLMETBRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
US-8569295-B2 Bicyclic urea compounds MERCK PATENT GMBH (DE) 2013-10-29 US disclosed
EP-2461869-B1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2013-08-21 EP disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2012-07-26 US disclosed
WO-2011017142-A1 NOVEL BICYCLIC UREA COMPOUNDS MERCK PATENT GMBH (DE) 2011-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120190654-A1 NOVEL BICYCLIC UREA COMPOUNDS CCNC, CCNI, CCNA1 AXL 1732/4885ALPL 3090/4885LMNA 3088/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.